On Sep 20, IVERS-READ GILLIAN C, See Remarks sold 837 shares of Clovis Oncology Inc. (NASDAQ: CLVS), with the average selling price of the stock being $4.80 per share. The total amount realized from this sold $4,018. A document was filed with the Securities and Exchange Commission to notify the public about the sold of the shares.
In addition to that, See Remarks – Rolfe Lindsey sold an extra 1,744 shares of this stock in a transaction that took place a day before, on Sep 20, with a share sold at an average of $4.80 and a total of $8,371 was realized from this transaction. After the transaction, the See Remarks – Rolfe Lindsey was left with 23,881 shares of the company’s stock, which is currently worth around $114628.8.
The recent price movement of CLVS means that it is now down by -89.58% from its 52-week high and 10.96% up against its 52-week low prices. Over the past one week, the price volatility of CLVS stands at 10.77% while the volatility over the past one month is 8.82%. The beta score for this stock is 1.79. A beta score below 1 means that the stock has a low volatility while above 1 signifies that a stock is highly volatile at that particular moment, a data that traders use to keep tabs on their investments.
The company published its latest quarterly earnings, with the report showing that the company recorded -1.71 earnings per share (EPS) during that period. This report was below the expectations of analysts of -1.6 by -0.11. The revenue by the firm was 35.84M for the quarter.
The shares of Clovis Oncology Inc. (CLVS) dropped by -8.74%, leading to a loss of -$0.32 per share, and saw CLVS end the trading session at $3.34 on Friday 10/18/19. CLVS started the trading session at $3.70, before reaching a daily high of $3.75. It wasn’t able to sustain that growth though and soon jumped to hit a daily low of $3.29.
The trading volume on Friday stood at 3353938, which was below the stock’s 3-month average volume of 3.90 million shares, out of a total 52.93M shares. As the price of the stock dipped, the market valuation of the company dropped to 200.00 million.
The shares of Antero Resources Corporation (NYSE: AR) went down by -8.93% by the end of the recent trading session. This movement saw its price plunge to close at $2.55, which was lower than the previous closing price of $2.80. Over the past one week, the price of AR has slipped by -6.59%, while it has recorded a loss of -32.89% over the past one month. Its three-month performance saw AR lose -48.69% while its six-month performance saw it drop by -68.28%. The situation is different though over the past one year, as the stock price went down by -86.43%, while its year-to-date (YTD) price performance slipped by -72.84%. The stock price has gone up by +7.14% compared to its 90-day low, while it is down -50.20% compared to its 90-day high price.
Let’s take a look at its short, medium and long-term indicators. Composite Indicators shows that Trendspotter rated the stock as a Sell. In the short-term, the stock has a 20-day average volume of 10,654,835 shares, with the short-term indicators averagely rating the stock as a 100% Sell. A look at its medium-term indicators reveals that it has a 50-Day average volume of 10,976,302 shares and the indicators have an average rating of 100% Sell. The last indicators, the long-term see AR stock with a 100-Day average volume of 10,424,550 shares, giving it an average rating of 100% Sell. A look at the general picture of all short, medium and long-term indicators leaves AR with an average rating of 100% Sell.
Several brokerage firms sent out their reports AR stock not long ago. In its report sent out on October 04, 2019, Morgan Stanley lowered its ratings on AR from a Equal-Weight to a Underweight. In an earlier report on October 03, 2019, JP Morgan Resumed the stock to a Underweight. Goldman meanwhile in its report on September 06, 2019 Downgrade its rating of the stock from a “Neutral” to “Neutral”.
In related news to the company’s stock, around 98.60% shares are being held by institutional investors. In a recent SEC filing, the company revealed that 311 institutions currently hold the AR stock. In the last quarter, a 298,519,911 AR shares were in the possession of institutions. On the other hand, the company recorded 41 new institutions who bought it their stock, while 52 institutions sold their entire AR reserve. Of the current institutions investing in the stock, 130 increased their investment while 141 decreased their investment in the stock.